The round was led by General Catalyst with participation from new and existing investors, including 7wire Ventures, Ingeborg Investments, Accel, Box Group, Leaps by Bayer, and Up2 Opportunity Fund. With $26.2M million in total capital, this new funding will fuel WellTheory's commercial growth, accelerate AI development, and expand programs that meet growing demand from employers and payors.

WellTheory is a virtual care platform reversing the autoimmune epidemic by filling the gaps left behind in traditional healthcare. WellTheory offers a research-backed proprietary program that addresses the root cause of autoimmunity and treats the whole person with the aim to reduce symptoms, improve quality of life, and lower costs. WellTheory's platform centers around evidence-based, high-touch care led by an interdisciplinary team of autoimmune experts, including licensed registered dietitians and board-certified health coaches. It's an anti-symptom-masking model that goes beyond the pill, built by autoimmune patients and validated by decades of clinical research.